Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0766 • ACR Convergence 2022
CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients
Nilasha Ghosh¹, Diviya Rajesh¹, Jessica Kirschmann², Deanna Jannat-Khah, DrPH, MSPH¹, Karmela Kim Chan¹, Susan Goodman¹, Vivian Bykerk¹, William Robinson³ and Anne Bass⁴, ¹Hospital for Special Surgery, New York, NY, ²Stanford University, Stanford, CA, ³Stanford University School of Medicine, Palo Alto, CA, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) have markedly improved the treatment of many advanced cancers; however, they can result in immune-related adverse events (irAE) including ICI-inflammatory…
Abstract Number: 0886 • ACR Convergence 2022
Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study
Rachel Giblon¹, Sara Achenbach², Elena Myasoedova¹, John Davis¹, Vanessa Kronzer¹ and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic, Eyota, MN
Background/Purpose: Depression and anxiety are known to occur more commonly in patients with RA. For example, recent studies estimate a depression point-prevalence of 17% in…
Abstract Number: 0902 • ACR Convergence 2022
Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method
Yusuke Miwa¹, Yuko Mitamura², Hiroi Tomioka³ and Michio Hosaka⁴, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Tokyo, Japan, ³Department of Psychiatry, School of Medicine, Yokohama, Japan, ⁴Department of psychosomatic medicine, Fujiyoshida, Japan
Background/Purpose: It has been reported that about 15% of patients with rheumatoid arthritis (RA) have depression, and most of these studies have used questionnaire methods.…
Abstract Number: 0918 • ACR Convergence 2022
Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study
BERNARD COMBE¹, Yoshiya Tanaka², Maya Buch³, Gerd Burmester⁴, Beatrix Bartok⁵, Alena Pechonkina⁶, Ling Han⁶, Kahaku Emoto⁷, Shungo Kano⁷, Thijs Hendrikx⁸ and Daniel Aletaha⁹, ¹Montpellier University, Montpellier, France, ²University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Gilead Sciences, Inc., La Jolla, CA, ⁶Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, K.K., Tokyo, Japan, ⁸GLPG, Leiden, Netherlands, ⁹Medical University Vienna, Wien, Austria
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) and poor prognostic factors1 (PPF) are at risk for progression without adequate treatment. Filgotinib (FIL) is a once…
Abstract Number: 0935 • ACR Convergence 2022
Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
Giorgio CASABURI, Tyler O'Malley, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity. RA affects approximately 0.5/1% of adults in the…
Abstract Number: 1144 • ACR Convergence 2022
Circulating miRNAs and Difficult-To-Treat Rheumatoid Arthritis: The Screening Study
Jiří Baloun¹, Aneta Pekčcová², Heřman Mann³, Jiří Vencovský⁴, Karel Pavelka⁵ and Ladislav Šenolt⁴, ¹Institue of Rheumatology, Prague, Czech Republic, ²Institue of Rheumatology, Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic
Background/Purpose: Biologic (b-) and targeted synthetic (ts-) disease-modifying antirheumatic drugs (DMARDs) have brought significant progress in the treatment of rheumatoid arthritis (RA), but a significant…
Abstract Number: 1260 • ACR Convergence 2022
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Irina Gessl¹, Mihaela Popescu², Gabriela supp³, Thomas Deimel¹, Paul Studenic¹, Martina Durechova³, michael zauner³, Josef Smolen¹ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: In inflammatory arthritis swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, the association of tenderness with radiographic…
Abstract Number: 1358 • ACR Convergence 2022
Adherence to Early DMARD Strategies in Newly Diagnosed RA Patients Seen in Routine Care: Results from the Canadian Early Arthritis Cohort Study
Yuxuan Jiang¹, orit schieir², Marie-France Valois², Susan Bartlett³, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Vivian Bykerk¹¹, Janet Pope¹² and Canadian Early Arthritis Cohort (CATCH) Investigators¹³, ¹Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada, ²McGill University, Montréal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²University of Western Ontario, London, ON, Canada, ¹³The Canadian Early Arthritis Cohort (CATCH), Bowmanville, ON, Canada
Background/Purpose: Early diagnosis coupled with early intensive treatment strategies have led to marked improvements in rheumatoid arthritis (RA) patient outcomes. Despite improved access to numerous…
Abstract Number: 1402 • ACR Convergence 2022
Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
Xiuying Li¹, Angela Cesta¹, Mohammad Movahedi² and Claire Bombardier³, ¹University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late onset rheumatoid arthritis (LORA) is a…
Abstract Number: 1419 • ACR Convergence 2022
Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Rieke Alten¹, Gerd Burmester², Marco Matucci-Cerinic³, Andrew Ostor⁴, Liliana Zaremba-Pechmann⁵, Tamas Treuer⁶, Khai Jing Ng⁶, Jens Gerwien⁶, Kathryn Gibson⁷ and Bruno Fautrel⁸, ¹SCHLOSSPARK KLINIK, University Medicine Berlin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³University of Florence, Florence, Italy, ⁴Cabrini Hospital, Monash University & Emeritus Research, Melbourne, Australia, ⁵HaaPACS GmbH, Schriesheim, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, United States of America, Sydney, Australia, ⁸Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France
Background/Purpose: RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time to discontinuation of initial RA treatment. Baricitinib…
Abstract Number: 1439 • ACR Convergence 2022
Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections
Alan Smith¹, Pei-Ling Roerig¹, Jacob Cason², David Fancis², Brian Cooley², Mike Royal³, Vibeke Strand⁴, John Goldman⁵, Roel Querubin⁶ and Russell Ross², ¹4P Therapeutics, Peachtree Corners, GA, ²Sorrento Therapeutics, Atlanta, GA, ³Sorrento Therapeutics, San Diego, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Northside Hospital, Atlanta, GA, ⁶Atlanta Research Center for Rheumatology, Marietta, GA
Background/Purpose: The lymphatic system plays an integral role in the pathology of rheumatoid arthritis (RA)1 and mediates local RA flares2, yet most biologic therapies are…
Abstract Number: 1645 • ACR Convergence 2022
Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis
Mehreen Soomro¹, Michael Stadler¹, Sebastien Viatte¹, Alex Macgregor², Suzanne Verstappen¹, Anne Barton¹ and John Bowes¹, ¹The University of Manchester, Manchester, United Kingdom, ²The University of East Anglia, Norwich, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher prevalence of coronary artery disease (CAD) than the general population, which contributes to early mortality. However,…
Abstract Number: 1740 • ACR Convergence 2022
Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity
Tessnime Abaab¹, Lyna Mebrek¹, Marie-Christophe Boissier², Luca Semerano³, Jerome Biton¹ and Natacha Bessis¹, ¹INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France, ²INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ³Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are inflammatory autoimmune diseases associated with impaired regulatory T cell (Tregs) function. Tregs identity varies according to their…
Abstract Number: 1778 • ACR Convergence 2022
More Than Half of RA Patients with a Lifetime History of Mood Disorders or Anxious and Depressed During COVID-19 Pandemic
Susan Bartlett¹, orit schieir², Marie-France Valois², Diane Tin³, Glen Hazlewood⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Janet Pope⁸, Carter Thorne⁹ and Vivian Bykerk¹⁰, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³The Arthritis Program Research Group, Newmarket, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁶Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Chronic stress and chronic disease are risk factors for anxiety and depression. In Canadians with RA, pandemic-related stress was exacerbated by delayed access to…
Abstract Number: 1961 • ACR Convergence 2022
COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age
Holly Dudley¹, megan O'Mara², Ann Auma¹, Jenny Gong³, Yael Ross⁴, Natalie Gurevich², Larraine Gordesky⁵, Nora Singer⁶, Lenche Kostadinova⁷, Brigid Wilson⁷, David Zidar⁷, Christopher King¹, David Canaday¹, Carey Shive¹, Maya Mattar⁸ and Donald Anthony⁹, ¹Case Western Reserve University, Cleveland, OH, ²Cleveland Veteran Affairs Medical Center, Cleveland, OH, ³Case Western School of Medicine, Cleveland, OH, ⁴Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, ⁵MetroHealth Medical Center, Cleveland, OH, ⁶The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁷VA Medical Center, Cleveland, OH, ⁸Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁹Case, VA, Metro, Chardon, OH
Background/Purpose: People with autoimmune diseases have worse outcomes if infected by SARS-CoV2. In particular, persons with rheumatoid arthritis (RA), have lower antibody responses to COVID-19…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].